HRT Financial’s Citius Pharmaceuticals CTXR Stock Holding History

HRT Financial’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-60,332	Closed	-$54K	–	4405
2026 Q1	$54K	Buy	+60,332	New	+$48.7K	﹤0.01%	3443
2024 Q4	–	Sell	-1,487	Closed	-$18K	–	2550
2024 Q3	$18K	Sell	1,487 -2,517	-63%	-$42.4K	﹤0.01%	2196
2024 Q2	$58K	Buy	+4,004	New	+$71.7K	﹤0.01%	1817
2022 Q1	–	Sell	-3,635	Closed	-$139K	–	3231
2021 Q4	$139K	Buy	+3,635	New	+$165K	﹤0.01%	2670

Other funds holding CTXR

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MFS

Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

AAG

Asset Advisory Group Kinnelon, New Jersey $229M AUM

HRT Financial's CTXR Position: Q2 2026 in Review

HRT Financial sold out of Citius Pharmaceuticals (CTXR) in Q2 2026, closing a stake of 60,332 shares — an estimated $54K sold.

HRT Financial first reported a position in CTXR in Q4 2021 and held it in 4 quarters. The position peaked at $139K in Q4 2021. 43 funds tracked by Wall St. Rank hold CTXR as of Q2 2026.

HRT Financial reported no remaining Citius Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
HRT Financial sold 60,332 Citius Pharmaceuticals shares in Q2 2026, an estimated $54K.
HRT Financial first reported a position in Citius Pharmaceuticals in Q4 2021 and held it in 4 quarters.
HRT Financial's Citius Pharmaceuticals position peaked at $139K in Q4 2021.
43 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.